Tirzepatide 10mg 'fractional' dosing: what the caption isn't telling you

What did @atendentekeyliane actually say?

The spoken transcript is, frankly, incoherent. The audio appears to be unrelated to the product being promoted, full of disconnected references to New York students and elevator engineers. The real claim lives in the caption: a 10mg tirzepatide vial described as "fracionável" (fractional-dose), marketed as "sufficient treatment for 2 to 3 months."

That caption claim is doing a lot of heavy lifting. It implies a single compounded vial can replace two to three months of a prescribed GLP-1 regimen, which is a dosing and safety claim, not just a product description. The creator does not mention a prescriber, a titration schedule, or any clinical context. The product is presented as a ready-to-use, self-directed solution for an unstated condition, most likely weight management.

Does the science back this up?

Tirzepatide itself has strong clinical evidence. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed that participants on 15mg tirzepatide lost a mean of 20.9% of body weight over 72 weeks. That data is real and impressive. But that data applies to pharmaceutical-grade tirzepatide, dosed under medical supervision, titrated from 2.5mg upward.

The "2 to 3 months from one vial" framing does not map onto any approved protocol. The standard titration for tirzepatide starts at 2.5mg weekly and increases every four weeks. A 10mg vial, fractioned into weekly injections, would cover roughly four to five doses at lower titration levels, not a stable therapeutic 2-to-3-month course at an effective dose. The math does not support the claim, and no peer-reviewed study has validated this specific compounding and dosing approach.

What did they get wrong (or right)?

What they got right: tirzepatide is a legitimate, well-studied dual GIP/GLP-1 receptor agonist. Fractionated compounded peptides do exist in markets where brand-name versions are inaccessible or unaffordable. The demand is real.

What they got wrong is more significant. Calling a single 10mg vial sufficient for two to three months of treatment is misleading. At therapeutic doses of 5mg to 15mg weekly, a 10mg vial lasts one to two injections, not months. If the implied dose is far lower than therapeutic, the creator is implying efficacy at sub-therapeutic levels, which is not supported by SURMOUNT trial data. Beyond the math, there is no mention of cold-chain storage requirements, bacteriostatic water reconstitution, sterile technique, or the need for a licensed prescriber. Rodrigues et al. (2023, Obesity Reviews) flagged that informal compounded GLP-1 markets frequently lack quality controls that affect potency and sterility.

What should you actually know?

Compounded tirzepatide is not the same as Mounjaro or Zepbound. The FDA has been explicit about this. Compounded versions are not FDA-approved, have not been evaluated for safety or efficacy as compounded products, and the FDA issued a statement in 2024 noting it had received reports of adverse events tied to compounded semaglutide and tirzepatide, including dosing errors from unit confusion between mg and mcg.

If you are considering tirzepatide for weight management or glycemic control, the evidence supports its use under supervised titration with a licensed provider. The dose matters, the schedule matters, and the source matters. A caption promising months of treatment from a single vial, with no clinical framing, is a red flag worth taking seriously before purchasing anything.

• Tirzepatide requires a valid prescription in Brazil (RDC 204/2017 controlled substance framework) and most regulated markets.
• Compounded peptides must be prepared by a licensed compounding pharmacy (farmácia de manipulação) under ANVISA oversight to be legal in Brazil.
• No compounded version has bioequivalence data confirming it performs identically to the reference drug.